The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
HOME > COMMENTARY
COMMENTARY
- Pricing Reform Could Goad Drug Makers to Focus Resources on PMP Hopefuls
December 28, 2017
- Unraveling MHLW/MOF Tug-of-War on Drug Pricing Reform
November 8, 2017
- With Study Group on Counterfeit Drugs to Resume Discussions this Fall, Full-Scale Discussions on Introduction of PIC/S GDP Guidelines Looming
October 10, 2017
- Epigenetic Drug Discovery Efforts Expanding, with Solid Cancers Now Being Targeted
September 1, 2017
- MHLW Panel Elaborating Rules for Clinical Research Law, “Scholarship Donations” to Be a Major Focus
August 21, 2017
- Xarelto Survey Scandal Calls into Question Bayer’s Organizational Setup, Employee Ethics
July 26, 2017
- Did Voice of the Industry Reach Honebuto Policymakers?
June 21, 2017
- As AG Momentum Continues, Mucosta AG to Hit Shelves 8 Years after Gx Entry
June 14, 2017
- MHLW, MOF Agreed on CEFP Working Group Report, Continuation of Premium As-Is Seems Difficult
May 11, 2017
- Will Government Take the Lead in Pricing Debate towards 2017 Fiscal Blueprint?
April 19, 2017
- “Cash-and-Carry Dealers” and Their Peculiar Business Practices in the Spotlight in Wake of Counterfeit Harvoni Scandal
April 12, 2017
- Is the Government’s 70% Interim Generic Share Target Achievable?
March 13, 2017
- Growing Hopes for Control of Hepatic Cancer; Road to Cures for Hepatitis B, NASH Might Be in Sight
March 7, 2017
- Will NHI Pricing Reform in Sluggish Domestic Market Trigger Industry Reorganization?
February 6, 2017
- Top-Notch Talents Needed for Pharma’s Lobbying Activities; Stay Current with Policymaking Moves
January 30, 2017
- Hepatology Society Revises Hep C Treatment Guidelines; Looking to Future Research for Non-Responders to IFN-Free Treatment
December 14, 2016
- Taltz Issue Exposes Forex-Sensitive Nature of Drug Pricing System
November 15, 2016
- Are Biosimilars on Verge of Breakthrough in Japan? Initiatives Underway to Prepare for Full-Scale Entry of Major Biosimilars
October 25, 2016
- Policymakers Face Balancing Act over Opdivo Re-Pricing
October 17, 2016
- Can Wholesalers Bear Distribution Costs amid 90% Discount on Generics?
October 11, 2016
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…